Clinical Trials: Page 141
-
Acacia Pharma braces for approval of potential blockbuster post-op nausea drug
Acacia is hoping that ADP421 will become a mainstay in treating post-operative nausea and vomiting, one of the most common surgical complications.
By Nicole Gray • Oct. 7, 2014 -
Nobel committee announces 2014 winners in Physiology or Medicine
The prize was awarded for "discoveries of cells that constitute a positioning system in the brain."
By Nicole Gray • Oct. 6, 2014 -
Explore the Trendline➔
Getty Images
TrendlineNeuroscience drug development
Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.
By BioPharma Dive staff -
Novartis and BMS co-testing lung cancer therapies
Novartis is testing three of its lung cancer drugs in combo with one of the most talked-about cancer immunotherapy drugs in development.
By Nicole Gray • Oct. 6, 2014 -
Optos to collaborate with UK government and universities
The $16-million collaboration is intended to develop cutting-edge optical imaging technology.
By Nicole Gray • Oct. 6, 2014 -
Lilly abandons lupus drug after late-stage trial failures
Some data were good for Lilly’s lupus drug, tabalumab, but overall the data were not strong enough to move forward.
By Nicole Gray • Oct. 3, 2014 -
Study: NSAID-related GI bleeding risk increases with combo therapy
It’s a bad idea to take Advil for a long period of time, and an even worse idea to take Advil with prednisone or warfarin, according to a study published in the latest issue of Gastroenterology.
By Nicole Gray • Oct. 3, 2014 -
EMA expands clinical data access to researchers and public
The European Medicines Agency has made the data available to the public with very few restrictions.
By Nicole Gray • Oct. 3, 2014 -
Pfizer, Kyowa Hakko Kirin partner on immuno-oncology study
The immuno-oncology revolution continues as Pfizer and Kyowa—a leading Japanese biopharma company—work together to develop solid tumor treatments.
By Nicole Gray • Oct. 2, 2014 -
Tekmira stock opens big on news of first US Ebola case
As the CDC announced the first locally diagnosed case of Ebola in a Texas hospital, investors rushed to Tekmira and its experimental TKM-Ebola.
By Sy Mukherjee • Oct. 1, 2014 -
Roche's Perjeta 'unprecedented' in extending breast cancer patients' lives
"Phenomenal," "unprecedented," and "practice-changing" are just a few of the superlatives being heaped on this treatment for aggressive, metastatic breast cancer.
By Sy Mukherjee • Sept. 29, 2014 -
Shareholders bullish on Nicox after phase III glaucoma trial
Vesneo (latanoprostene bunod), licensed to Valeant/Bausch & Lomb by Nicox, has been capturing the ophthalmology community's attention.
By Nicole Gray • Sept. 29, 2014 -
US doc treated with Tekmira Ebola drug declared virus free
Dr. Richard Sacra is the third American Ebola patient to be discharged and the first to be released after treatment with TKM-Ebola.
By Sy Mukherjee • Sept. 25, 2014 -
FDA to review Otsuka and Lundbeck's potential schizophrenia game changer
If approved, brexpiprazole is expected to succeed Otsuka's popular antipsychotic Abilify.
By Sy Mukherjee • Sept. 25, 2014 -
How the NIH is trying to get more women to participate in clinical trials
Male cells are disproportionately used in the preclinical setting, even though male and female cells react differently to both diseases and treatment.
By Nicole Gray • Sept. 24, 2014 -
UPDATED: Tekmira tempers expectations as regulators clear Ebola drug for emergency use
Patients in the U.S. and Canada will have access to TKM-Ebola, while a charitable organization is issuing grants to expedite clinical trials of the drug and two other Ebola treatments.
By Sy Mukherjee • Sept. 23, 2014 -
Study: Just one dose of antidepressant changes brain connectivity
The research finds that one dose of an SSRI increases connectivity in the cerebellum and the thalamus.
By Nicole Gray • Sept. 22, 2014 -
AZ's new formulation performs well in phase III diabetes study
In a 28-week study, exanatide once-weekly suspension for autoinjection was as effective as twice-daily exanatide injection for glycemic control.
By Nicole Gray • Sept. 22, 2014 -
Lilly enters crowded diabetes field as FDA approves once-weekly Trulicity
Can the clinically impressive once-weekly treatment compete with Novo's Victoza?
By Sy Mukherjee • Sept. 19, 2014 -
Gilead's pancreatic cancer hopeful crashes in phase II
Progression-free survival didn't budge even when researchers combined simtuzumab with standard of care in high doses.
By Nicole Gray • Sept. 18, 2014 -
Avanir Pharma soars to 8-year high on positive Alzheimer's drug results
AVP-923 could become a first-in-class treatment for agitation in Alzheimer’s disease patients.
By Nicole Gray • Sept. 16, 2014 -
Roche starts phase III trials for advanced wet AMD drug
If approved, lampalizumab will become the first treatment for advanced wet macular degeneration---also known as geographic atrophy.
By Nicole Gray • Sept. 16, 2014 -
Roche's cheaper vision loss drug just as effective as Novartis' Lucentis
Novartis’ Lucentis and Roche’s Avastin are similarly effective against wet age-related macular degeneration. But only one is approved for treating the condition -- even though the other is far cheaper.
By Nicole Gray • Sept. 16, 2014 -
Asterias, Cancer Research UK to collaborate on lung cancer vaccine
The companies will be hoping for better results than Merck KGaA, which was forced to shut down its own lung cancer vaccine trial last week.
By Nicole Gray • Sept. 15, 2014 -
Dompé bullish on novel eye disease treatment
Italy-based Dompé has successfully completed clinical studies on a novel new treatment for the incurable neurotrophic keratitis.
By Nicole Gray • Sept. 15, 2014 -
FDA approves controversial weight loss pill Contrave
The second time's the charm for Orexigen and Takeda's highly-anticipated weight loss drug.
By Sy Mukherjee • Sept. 11, 2014
Previous
